Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
Heart Matters
Advances in ATTR-CM: Evolving Diagnostics and Therapeutics
- Kevin Alexander
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
CME/CE
No Patient with CKD Left Behind! Emerging CKD Therapies in T1D
0.50 credits
- Richard E. Pratley, MD
- David Cherney, MD, PhD
- prof. Hiddo Heerspink
0.50 credits
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
On the Frontlines of ATTR-CM
Patient Voices in ATTR-CM: Driving Change in Diagnosis, Referral, and Support
- Ryan Quigley
- Quan Bui, MD
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
Heart Matters
Treating ATTR-CM Early: A Shift From Reactive to Strategic Care
- Quan Bui, MD
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Heart Matters
ATTR-CM Trials Revisited: A Broader View of Treatment Benefit
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
Heart Matters
Closing Gaps in ASCVD Prevention: Lipid Management Insights from AHA 2025
- Laurence Sperling, MD
- Eugenia Gianos, MD
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Cardiology
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
- Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
Cardiology
Advancing Care for Women With Aortic Stenosis: 2-Year Outcomes for Women in the 5-Year SMART Trial
- Roxana Mehran, MD, FSCAI

Programs

Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
AudioAbstracts
Exploring Tafamidis Survival Data in Elderly Patients with ATTR-CM
- Hallie Blevins, PhD
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
Heart Matters
Advancing Diagnosis of Transthyretin Cardiac Amyloidosis in Underserved Populations
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
AudioAbstracts
From HCM to ATTR-CM: Rethinking Unexplained Hypertrophy
- Hallie Blevins, PhD
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Heart Matters
Understanding Diagnostic Gaps Among Medicare Patients with ATTRwt-CM
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
CME/CE
Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
0.25 credits
- Erin Bohula, MD, DPhil
- Lawrence Leiter
0.25 credits
Highlights of the Latest Hypertension Guidelines
Highlights of the Latest Hypertension Guidelines
Cardiology
Highlights of the Latest Hypertension Guidelines
- Clyde W. Yancy, MD
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
CME/CE
Engaging Your Patient: Shared Decision-Making in HF With LVEF ≥40%
0.25 credits
- Scott Solomon, MD
0.25 credits
The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits

Clinical Practice

Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
Heart Matters
Redefining ATTR Treatment: Key Mechanisms and Emerging Data
- Ahmad Masri, MD, MS
Clinical Perspective on New Therapies in Resistant Hypertension
Clinical Perspective on New Therapies in Resistant Hypertension
Cardiology
Clinical Perspective on New Therapies in Resistant Hypertension
- Clyde W. Yancy, MD
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Heart Matters
Targeting Vascular KCNQ5 Channels: A Promising Strategy for Blood Pressure Control
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CM
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
- Shelina Ramnarine, PhD
- Quan Bui, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Cardiology
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Cardiology
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Ambarish Pandey, MD
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Cardiology
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
- Clyde W. Yancy, MD
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
Cardiology
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
- Erin Michos

CME

The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
CME/CE
The Hidden Threat: Transforming CKD Care Across the Diabetes Spectrum 
0.50 credits
- prof. Hiddo Heerspink
- Peter Rossing, MD, DMSc
- Paola Fioretto, MD
0.50 credits
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
MinuteCE®
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
MinuteCE®
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit